TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

NCT05188313 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

376

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Esophageal Adenocarcinoma

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)